vs
罗致恒富（RHI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
罗致恒富的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Revvity同比增速更快（5.9% vs -5.8%），罗致恒富自由现金流更多（$170.8M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs -6.1%）
罗致恒富是1948年成立的国际人力资源咨询机构，总部位于加利福尼亚州门洛帕克和圣拉蒙，是全球规模领先的会计与金融领域人才派遣服务商之一，在全球范围内设有超过345个办公点。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
RHI vs RVTY — 直观对比
营收规模更大
RHI
是对方的1.7倍
$772.1M
营收增速更快
RVTY
高出11.6%
-5.8%
自由现金流更多
RHI
多$9.0M
$161.8M
两年增速更快
RVTY
近两年复合增速
-6.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | — | $98.4M |
| 毛利率 | 37.6% | — |
| 营业利润率 | 1.7% | 14.5% |
| 净利率 | — | 12.7% |
| 营收同比 | -5.8% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $0.32 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RHIRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.4B | $698.9M | ||
| Q2 25 | $1.4B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.4B | $729.4M | ||
| Q3 24 | $1.5B | $684.0M | ||
| Q2 24 | $1.5B | $691.7M | ||
| Q1 24 | $1.5B | $649.9M |
净利润RHIRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $42.9M | $46.7M | ||
| Q2 25 | $41.0M | $53.9M | ||
| Q1 25 | $17.4M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $65.5M | $94.4M | ||
| Q2 24 | $68.2M | $55.4M | ||
| Q1 24 | $63.7M | $26.0M |
毛利率RHIRVTY
| Q4 25 | 37.6% | — | ||
| Q3 25 | 37.2% | 53.6% | ||
| Q2 25 | 37.2% | 54.5% | ||
| Q1 25 | 36.9% | 56.5% | ||
| Q4 24 | 38.8% | — | ||
| Q3 24 | 39.0% | 56.3% | ||
| Q2 24 | 39.2% | 55.7% | ||
| Q1 24 | 38.1% | 54.6% |
营业利润率RHIRVTY
| Q4 25 | 1.7% | 14.5% | ||
| Q3 25 | 1.0% | 11.7% | ||
| Q2 25 | 0.1% | 12.6% | ||
| Q1 25 | 2.9% | 10.9% | ||
| Q4 24 | 4.7% | 16.3% | ||
| Q3 24 | 4.1% | 14.3% | ||
| Q2 24 | 5.1% | 12.4% | ||
| Q1 24 | 2.8% | 6.8% |
净利率RHIRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 3.2% | 6.7% | ||
| Q2 25 | 3.0% | 7.5% | ||
| Q1 25 | 1.3% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 4.5% | 13.8% | ||
| Q2 24 | 4.6% | 8.0% | ||
| Q1 24 | 4.3% | 4.0% |
每股收益（稀释后）RHIRVTY
| Q4 25 | $0.32 | $0.86 | ||
| Q3 25 | $0.43 | $0.40 | ||
| Q2 25 | $0.41 | $0.46 | ||
| Q1 25 | $0.17 | $0.35 | ||
| Q4 24 | $0.53 | $0.77 | ||
| Q3 24 | $0.64 | $0.77 | ||
| Q2 24 | $0.66 | $0.45 | ||
| Q1 24 | $0.61 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $464.4M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $7.3B |
| 总资产 | $2.9B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RHIRVTY
| Q4 25 | $464.4M | $919.9M | ||
| Q3 25 | $365.3M | $931.4M | ||
| Q2 25 | $380.5M | $991.8M | ||
| Q1 25 | $342.5M | $1.1B | ||
| Q4 24 | $537.6M | $1.2B | ||
| Q3 24 | $570.5M | $1.2B | ||
| Q2 24 | $547.4M | $2.0B | ||
| Q1 24 | $540.9M | $1.7B |
股东权益RHIRVTY
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.3B | $7.4B | ||
| Q2 25 | $1.3B | $7.6B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.4B | $7.7B | ||
| Q3 24 | $1.5B | $7.9B | ||
| Q2 24 | $1.5B | $7.9B | ||
| Q1 24 | $1.5B | $7.8B |
总资产RHIRVTY
| Q4 25 | $2.9B | $12.2B | ||
| Q3 25 | $2.8B | $12.1B | ||
| Q2 25 | $2.8B | $12.4B | ||
| Q1 25 | $2.7B | $12.4B | ||
| Q4 24 | $2.9B | $12.4B | ||
| Q3 24 | $3.0B | $12.8B | ||
| Q2 24 | $2.9B | $13.4B | ||
| Q1 24 | $2.9B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $182.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $170.8M | $161.8M |
| 自由现金流率自由现金流/营收 | 13.1% | 21.0% |
| 资本支出强度资本支出/营收 | 0.9% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $266.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流RHIRVTY
| Q4 25 | $182.5M | $182.0M | ||
| Q3 25 | $77.4M | $138.5M | ||
| Q2 25 | $119.4M | $134.3M | ||
| Q1 25 | $-59.3M | $128.2M | ||
| Q4 24 | $154.8M | $174.2M | ||
| Q3 24 | $129.6M | $147.9M | ||
| Q2 24 | $142.0M | $158.6M | ||
| Q1 24 | $-15.9M | $147.6M |
自由现金流RHIRVTY
| Q4 25 | $170.8M | $161.8M | ||
| Q3 25 | $63.6M | $120.0M | ||
| Q2 25 | $104.2M | $115.5M | ||
| Q1 25 | $-71.7M | $112.2M | ||
| Q4 24 | $140.5M | $149.8M | ||
| Q3 24 | $111.8M | $125.6M | ||
| Q2 24 | $129.6M | $136.6M | ||
| Q1 24 | $-27.7M | $129.7M |
自由现金流率RHIRVTY
| Q4 25 | 13.1% | 21.0% | ||
| Q3 25 | 4.7% | 17.2% | ||
| Q2 25 | 7.6% | 16.0% | ||
| Q1 25 | -5.3% | 16.9% | ||
| Q4 24 | 10.2% | 20.5% | ||
| Q3 24 | 7.6% | 18.4% | ||
| Q2 24 | 8.8% | 19.7% | ||
| Q1 24 | -1.9% | 20.0% |
资本支出强度RHIRVTY
| Q4 25 | 0.9% | 2.6% | ||
| Q3 25 | 1.0% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 0.9% | 2.4% | ||
| Q4 24 | 1.0% | 3.4% | ||
| Q3 24 | 1.2% | 3.3% | ||
| Q2 24 | 0.8% | 3.2% | ||
| Q1 24 | 0.8% | 2.7% |
现金转化率RHIRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 1.80× | 2.97× | ||
| Q2 25 | 2.91× | 2.49× | ||
| Q1 25 | -3.42× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 1.98× | 1.57× | ||
| Q2 24 | 2.08× | 2.87× | ||
| Q1 24 | -0.25× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
